Incyte Corporation maintained revenue guidance for 2024. For the year the company expects Jakafi net product revenues of $2,690 million to $2,750 million. The company expects other Hematology/Oncology net product revenues $325 million to $360 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.19 USD | +0.16% | -0.71% | -8.92% |
15/05 | Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM | |
13/05 | Equities Close Mixed as Markets Weigh Consumer Inflation Survey | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.92% | 12.84B | |
-3.15% | 89.69B | |
+3.95% | 41.34B | |
-10.51% | 33.72B | |
+58.75% | 26.11B | |
-20.09% | 14.63B | |
-11.46% | 11.66B | |
-43.05% | 11.52B | |
+4.72% | 8.92B | |
-10.64% | 8.38B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte Corporation Maintains Revenue Guidance for 2024